Count Me In’s legacy of data and resources will usher in a new way of doing research on other diseases and continue to fuel cancer studies around the globe.

An expert in epigenetics and longtime member of the Broad community, Buenrostro will focus on how life experiences can alter the epigenome and increase risk of disease.

A former drug discovery scientist, Gail Guo now helps advance research into novel cancer drugs as part of Broad’s alliance with Bayer.

Antibody–bottlebrush conjugates expand the options for drug cargos compared to antibody–drug conjugates.

Broad scientists describe how data resources they helped build over more than a decade now form the foundation for cutting-edge AI and genome biology discoveries.

A collaborative study between Dana-Farber Cancer Institute and the Broad Institute found that 8.9 percent of children with glioma, the most common form of pediatric brain tumor, have alterations in the fibroblast growth factor receptor (FGFR) family of proteins, and that these gliomas may be sensitive to existing U.S. Food and Drug Administration (FDA) approved inhibitors that broadly block FGFR.

Low-oxygen air prevented and even reversed symptoms in a mouse model of Parkinson’s disease.

Large analysis of genes and proteins in lung adenocarcinoma points to possible new diagnostic and treatment approaches, and also reveals signatures of chemical exposures in patients who have never smo...

OASIS consortium is evaluating omics tools in cells, including Cell Painting and transcriptomics, to predict liver toxicity of potential new medicines and agrochemicals.

A plate-based assay called CRAFTseq has been developed that uses ‘multi-omic’ single-cell RNA sequencing and direct genotyping of CRISPR edits to test the functional effects of genetic variants o...

Combining powerful imaging, perturbational screening, and machine learning, researchers uncover new human host factors that alter Ebola’s ability to infect.

Scientists use a precise form of gene editing called prime editing to correct the most common genetic mutations that cause alternating hemiplegia of childhood, a rare and severe neurological disorder ...

Klarman succeeds Eric Schmidt after four years as Chair; Aviv Regev joins the Board